×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
OTCMKTS:CURLF

Curaleaf Price Target, Predictions & Analyst Ratings

$5.07
-0.20 (-3.80%)
(As of 06/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.99
$5.27
50-Day Range
$5.11
$6.46
52-Week Range
$4.83
$14.80
Volume
573,499 shs
Average Volume
583,602 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.30

Curaleaf (OTCMKTS:CURLF) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$17.36
242.35% Upside
High Price Target$32.00
Average Price Target$17.36
Low Price Target$12.00
TypeCurrent
6/29/21 to 6/29/22
1 Month Ago
5/30/21 to 5/30/22
3 Months Ago
3/31/21 to 3/31/22
1 Year Ago
6/29/20 to 6/29/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.36$17.36$17.75$22.25
Predicted Upside242.35% Upside99.81% Upside94.92% Upside57.13% Upside
Get Curaleaf Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CURLF and its competitors with MarketBeat's FREE daily newsletter.


CURLF Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CURLF Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Curaleaf Stock vs. The Competition

TypeCuraleafMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.71
2.52
Consensus RatingModerate BuyBuyBuy
Predicted Upside229.36% Upside439.83% Upside32.68% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
145
83.33%
Underperform Votes
29
16.67%
Avg. Outperform Votes
170
67.19%
Avg. Underperform Votes
83
32.81%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical Curaleaf Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/10/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$15.50 ➝ C$14.50
5/10/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$25.00 ➝ C$24.00
5/10/2022MKM Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
William Kirk
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$14.00+149.55%
4/25/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$15.50 ➝ $16.50+155.42%
3/4/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$17.00 ➝ $15.00+145.50%
2/25/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+60.00%
1/7/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
11/9/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Scott Fortune
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$19.00 ➝ $16.00+55.04%
11/9/2021Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuyC$29.00 ➝ C$23.00
11/9/2021Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/7/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$32.00+131.88%
3/8/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
9/13/2019Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$11.00+48.13%
(Data available from 6/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Curaleaf Price Target - Frequently Asked Questions

What is Curaleaf's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Curaleaf stock is Moderate Buy based on the current 2 hold ratings and 8 buy ratings for CURLF. The average twelve-month price prediction for Curaleaf is $17.36 with a high price target of $32.00 and a low price target of $12.00. Learn more on CURLF's analyst rating history.

Do Wall Street analysts like Curaleaf more than its competitors?

Analysts like Curaleaf stock more than the stock of other Medical companies. The consensus rating for Curaleaf is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how CURLF compares to other companies.

Do MarketBeat users like Curaleaf more than its competitors?

MarketBeat users like Curaleaf stock more than the stock of other Medical companies. 83.33% of MarketBeat users gave Curaleaf an outperform vote while medical companies recieve an average of 67.19% outperform votes by MarketBeat users.

Does Curaleaf's stock price have much upside?

According to analysts, Curaleaf's stock has a predicted upside of 99.81% based on their 12-month price targets.

What analysts cover Curaleaf?

Curaleaf has been rated by Canaccord Genuity Group, Cantor Fitzgerald, MKM Partners, and Stifel Nicolaus in the past 90 days.

This page (OTCMKTS:CURLF) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.